drugset
drugset / Trial / NCT04947189

Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer

NCT04947189 ↗

Phase 1/2 Recruiting 65 enrolled St Vincent's Hospital, Sydney
NaSingle-groupOpen-labelTreatment

Summary

To facilitate the clinical testing of seviteronel and dexamethasone (SEVI-D) in combination with docetaxel in androgen receptor (AR) positive triple-negative breast cancer.

Timeline

Start
2022-11-01
Primary completion
2026-07
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 0.5 mg —
Subject Docetaxel Small molecule 75 mg/m2 Intravenous
Subject Seviteronel Small molecule 450 mg Oral

Indications

triple-negative breast carcinoma